Spatiotemporal dynamics of the tumor microenvironment in hepatocellular carcinoma during combination immunotherapy
Authors:
- Hitoshi IwasakiHIHitoshi Iwasaki
- Shinji ItohSIShinji Itoh
- Katsuya ToshidaKTKatsuya Toshida
- Junya MitaJMJunya Mita
- Takuma IshikawaTITakuma Ishikawa
- Norifumi IsedaNINorifumi Iseda
- Kyohei YugawaKYKyohei Yugawa
- Shohei YoshiyaSYShohei Yoshiya
- Takashi MotomuraTMTakashi Motomura
- Takeo ToshimaTTTakeo Toshima
- Shinichi AishimaSAShinichi Aishima
- Yoshinao OdaYOYoshinao Oda
Open Access
- 7 August 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (9)
Abstract
Background: Atezolizumab plus bevacizumab (ATZ/BEV) is a standard first-line therapy for advanced hepatocellular carcinoma (HCC); however, many patients do not achieve meaningful tumor regression. The temporal and spatial immune remodeling associated with ATZ/BEV remains poorly understood. Methods: We performed single-cell RNA sequencing of paired hepatectomy specimens obtained before and after ATZ/BEV from one patient and of tumor center and margin samples from another patient after ATZ/BEV. Cell composition, subclusters, and cell–cell communication were analyzed. In addition, candidate molecules identified by transcriptomic analysis were further assessed using serum-based assays and immunohistochemistry. Results: These single-cell analyses suggested that ATZ/BEV was associated with a shift toward an immune-active tumor microenvironment, with increased CD8 + T cells together with reduced endothelial cells. CD8 + T cells showed increased effector and exhaustion signatures, indicating coexistence of activation and dysfunction. CellChat analysis demonstrated selective activation of the TIGIT–PVR/NECTIN2 axis after treatment. Spatial analysis showed that the tumor margin was enriched for CD8 + T cells and exhibited stronger effector and exhaustion activity than the tumor center. Immunoregulatory signaling was also more prominent at the margin. Serum TIGIT levels were significantly higher after ATZ/BEV than in upfront resection cases ( p =0.0325). Immunohistochemistry showed greater margin-to-center differences in TIGIT ( p =0.0019) and PVR ( p =0.0008) in the tumor after ATZ/BEV. Conclusions: Our exploratory findings suggest that ATZ/BEV may remodel the HCC microenvironment toward a state characterized by concurrent CD8 + T-cell activation and inhibitory signaling through the TIGIT–PVR/NECTIN2 axis, particularly at the tumor margin.Keywords
This publication has 29 references indexed in Scilit:
- Survival impact and recurrence prediction using oncologic resectability classification in hepatocellular carcinoma following hepatic resection: a Japanese multi-center studyInternational Journal of Clinical Oncology, 2025
- Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinomaJournal of Hepatology, 2024
- Outcome of hepatectomy after systemic therapy for hepatocellular carcinoma: a Japanese multicenter studySurgery Today, 2024
- Association of serum lactate dehydrogenase with prognosis and tumor metabolism in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapySurgery Today, 2024
- Hot and cold tumors: Immunological features and the therapeutic strategiesMedcomm, 2023
- The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinomaHepatology, 2023
- Combination immunotherapy for hepatocellular carcinomaJournal of Hepatology, 2023
- Clinical effectiveness of surgical treatment after lenvatinib administration for hepatocellular carcinomaInternational Journal of Clinical Oncology, 2022
- Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular FormationHepatology, 2020
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialThe Lancet, 2018